Alzamend Neuro
ALZN
7 hedge funds and large institutions have $6.36K invested in Alzamend Neuro in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.17% more ownership
Funds ownership: 0.11% → 0.27% (+0.17%)
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
89% less capital invested
Capital invested by funds: $59.9K → $6.36K (-$53.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.47K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.95K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
+$99 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$37.1K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
-$14.7K |
| 3 |
Barclays
London,
United Kingdom
|
-$4.15K |
| 4 |
HIA
Harbor Investment Advisory
Lutherville,
Maryland
|
-$5 |
| 5 |
CSB
City State Bank
Norwalk,
Iowa
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $2.63K | +$4.47K | +902 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $2.32K | +$3.95K | +797 | New |
|
3
BlackRock
New York
| $1.28K | – | – | – |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $64 | +$99 | +20 | +1,000% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $55 | +$15 | +3 | +19% |
|
|
AWM
6
Activest Wealth Management
Aventure,
Florida
| $6 | – | – | – |
|
|
HIA
7
Harbor Investment Advisory
Lutherville,
Maryland
| $3 | -$5 | -1 | -50% |
|
|
8
Geode Capital Management
Boston,
Massachusetts
| – | -$37.1K | -4,350 | Closed |
|
|
9
Truist Financial
Charlotte,
North Carolina
| – | -$14.7K | -1,722 | Closed |
|
|
10
Barclays
London,
United Kingdom
| – | -$4.15K | -486 | Closed |
|
|
CSB
11
City State Bank
Norwalk,
Iowa
| – | -$4 | – | – |
|
12
Morgan Stanley
New York
| – | -$3 | – | – |
|
|
PA
13
Parallel Advisors
San Francisco,
California
| – | -$3 | – | – |
|
ALZN Hedge Fund Activity: Q2 2025 in Review
7 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q2 2025, worth a combined $6.36K — down 89% from $59.9K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ALZN and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, opening a new position worth an estimated $4.47K. The largest seller was Geode Capital Management, exiting entirely with an estimated $37.1K sold.
- 7 institutional investors held Alzamend Neuro (ALZN) as of Q2 2025, down from 8 in Q1 2025.
- Funds reported $6.36K of Alzamend Neuro stock for Q2 2025, down 89% quarter-over-quarter.
- 2 funds opened new Alzamend Neuro positions in Q2 2025 and 3 closed out, a net change of -1 holder.
- The largest Alzamend Neuro buyer in Q2 2025 was UBS Group, an estimated $4.47K added.
- The largest Alzamend Neuro seller in Q2 2025 was Geode Capital Management, an estimated $37.1K sold.
Based on aggregated 13F filings for Q2 2025.